Form 4: Fate Therapeutics Executive Receives Stock Options and Restricted Stock Units

Fate Therapeutics' Chief Regulatory and Quality Officer, Jerome Charles Bressi, was granted stock options and restricted stock units on January 15, 2025.

Summary

• Jerome Charles Bressi, Chief Regulatory and Quality Officer at Fate Therapeutics, received 65,000 restricted stock units and options to purchase 250,000 shares of common stock on January 15, 2025.
• The restricted stock units vest in four equal installments annually starting January 8, 2026, and ending January 8, 2029.
• The stock options vest in 36 equal monthly installments starting January 1, 2025, and will be fully vested by January 1, 2028.
• Both the restricted stock units and stock options are subject to Mr. Bressi's continued employment with Fate Therapeutics.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the stock options and restricted stock units is dependent on the future performance of Fate Therapeutics' stock price.
• The vesting of the awards is contingent on the executive's continued employment, creating a potential risk of forfeiture if employment is terminated.

Future Outlook

The document does not contain any forward-looking statements about the company's future performance.

Industry Context

This type of equity compensation is common practice for publicly traded biotechnology companies to incentivize and retain key executives.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the biotechnology industry.
• Vesting schedules of 3-4 years are typical for both stock options and restricted stock units in comparable companies such as CRISPR Therapeutics and Editas Medicine.
• The specific number of shares and option prices are company-specific and depend on the executive's role and the company's valuation.

Stakeholder Impact

• Shareholders may view this as a positive sign of management's commitment to the company.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, insider trading, Form 4, Fate Therapeutics, vesting